Savolitinib Drug News

On June 22, 2021, Savolitinib was first approved by the National Medical
Products Administration (NMPA) of China, indicated for the treatment of patients
with MET exon 14 skipping mutation-positive locally advanced or metastatic
non-small cell lung cancer (NSCLC) who have experienced disease progression
after systemic therapy or are unable to receive chemotherapy.

On March 1, 2023, Savolitinib was included in the National Reimbursement Drug
List (NRDL). It became the only MET-targeted agent successfully incorporated
into the NRDL through medical insurance negotiation, which significantly
improved patient access to the medication.

On January 13, 2025, Savolitinib received further approval from China’s NMPA,
expanding its indication from pretreated patients only to cover both
treatment-naive and pretreated adult patients with MET exon 14 skipping
mutation-positive locally advanced or metastatic NSCLC.